To assess the ex vivo cytokine production of whole blood during 28 days after phlebotomy (routine withdrawal of 500 ml of blood).
ID
Source
Brief title
Condition
- Haematological disorders NEC
- Immunodeficiency syndromes
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Change in ex vivo TNF-* production of whole blood, induced by incubation with
LPS, on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following the withdrawal of 500
ml of blood at the blood bank.
Secondary outcome
- the change in ex vivo production of other cytokines (IL-6, IL10) of whole
blood elicited by incubation with LPS, on day -1, 0, 1, 3, 5, 7, 14, 21 and 28
following the withdrawal of 500 ml of blood at the blood bank.
- Changes in hemoglobin, hematocrit, white blood cell count and differential on
day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following the withdrawal of 500 ml of
blood at the blood bank.
- Changes in plasma hepcidin concentration in the 28 days following the
withdrawal of 500 ml of blood at the blood bank
- Changes in other markers of iron homeostasis (serum iron, transferrin
saturation, ferritin) in the 28 days following the withdrawal of 500 ml of
blood at the blood bank
Background summary
The loss of blood by haemorrhage or routine phlebotomy as performed during
blood donation by healthy volunteers, has large effects on systemic iron
homeostasis. The relative shortage of erythrocytes after blood loss is
compensated for by increasing the production of new red cells by the bone
marrow. As iron is needed for effective haemoglobin synthesis, the transport of
iron to the bone marrow needs to be increased. This is accomplished by the
suppression of hepcidin production in the liver. Hepcidin is the central
regulator of iron homeostasis. It can regulate serum iron levels effectively by
downregulating iron channel ferroportin on iron exporting cells. Hepcidin
production is increased in response to inflammation en high systemic iron
content, and is suppressed by increased erythrocyte production, hypoxia,
anemia, and low systemic iron content. Therefore, blood loss leads to hepcidin
suppression, increased release of iron into the circulation and decrease of
iron stores.
Alterations in iron metabolism can have immunomodulatory effects. The intra
cellular iron content in macropahges and monocytes, has shown pro-inflammatory
effects in several investigations. Hepcidin is reported to have
pro-inflammatory effects in some reports, and anti-inflammatory effects in
others.
Although phlebotomy is routinely performed in blood donors, and seemingly does
not have significant health risks, it is highly relevant to know what the
effect of phlebotomy is on immunity. Alterations in immunity due to phlebotomy
could have beneficial effects, like the suppression of the low grade
inflammatory process that contributes to atherosclerosis, but in theory could
also contribute to a suppressed innate immune response that could increase the
risk of infection. This is not only relevant for blood donors, but also for
patients suffering from blood loss and for daily clinical practice in which
blood is routinely drawn of patients for laboratory determinations.
Study objective
To assess the ex vivo cytokine production of whole blood during 28 days after
phlebotomy (routine withdrawal of 500 ml of blood).
Study design
Prospective intervention study in 10 healthy male volunteers.
10 healthy volunteers will donate 500 mL at the blood bank, according to normal
procedures (day 0).
On day -1, 0, 1, 3, 5, 7, 14, 21 and 28 blood will be drawn for the
determination of:
- ex vivo cytokine production (TNF-alfa, IL-6, IL-10).
- hemoglobin, hematocrit and leucocyte differentiation.
- hepcidin.
- Iron parameters (serum iron, transferrin saturation, ferritin).
Intervention
Phlebotomy (withdrawal of 500 mL volbloed)
Study burden and risks
The study consists of 11 visits:
- 1 screening visit
- 1 phlebotomy visit
- 9 follow-up visits
At the screening, a questionaire will be filled out by the subject, and a short
physical examination will be performed.
At the visit for phlebotomy at the blood bank, another questionaire will be
filled out for registration purposes at the blood bank. Also, the hemoglobin
level will be checked. Then, a vene in the elbow will be puntured and 500 mL of
blood will be withdrawn.
At the follow-up visits, each time 2 tube of blood will be drawn (7 mL total).
Also, subjects will be questioned for the occurence of adverse events,
especially regarding intercurrent infections.
Geert Grooteplein-Zuid 10
Nijmegen 6525 GA
NL
Geert Grooteplein-Zuid 10
Nijmegen 6525 GA
NL
Listed location countries
Age
Inclusion criteria
- Male
- Age >18 and <36 years
- Healthy as concluded from medical history
Exclusion criteria
- Having donated blood to the blood bank within one year preceding phlebotomy
- Significant blood loss from trauma within one year preceding phlebotomy
- Having lost > 100 ml of blood due to any cause, within 3 months preceding phlebotomy (not counting blood withdrawn during screening visit)
- Having lost > 50 ml of blood due to any cause, within 1 month preceding phlebotomy (not counting blood withdrawn during screening visit)
- Having lost >20 ml blood due to any cause, within 1 week preceding phlebotomy
(not counting blood withdrawn during screening visit)
- Family history of thallasemia, sickle cell disease, hereditary hemochromatosis, or iron refractory iron deficiency anemia
- Signs of history of infection within 2 weeks preceding phlebotomy
- History of frequent vasovagal response
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCTnummervolgt |
CCMO | NL47674.091.14 |